The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Gotistobart in combination with pembrolizumab in patients with advanced melanoma who have progressed on PD-1 inhibitors with or without CTLA-4 inhibitors.
 
Siwen Hu-Lieskovan
Consulting or Advisory Role - Amgen; Cardinal Health; Delcath Systems; Endeavor BioMedicines; Immunocore; Replimune
 
Kari Kendra
Research Funding - GlaxoSmithKline (Inst); Immunocore (Inst); Merck (Inst); National Institute on Aging (Inst); The Melanoma Research Foundation (Inst); Varian Medical Systems (Inst)
 
Kai He
Consulting or Advisory Role - AstraZeneca; BioNTech SE; Bristol-Myers Squibb; Iovance Biotherapeutics; Lyell Immunopharma; Mirati Therapeutics; Obsidian Therapeutics; oncoc4; Perthera; Pfizer
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Iovance Biotherapeutics (Inst); Mirati Therapeutics (Inst); Oncoc4 (Inst)
 
Bently Doonan
Honoraria - Curis
Consulting or Advisory Role - Curis; Immunocore; Pfizer; Replimune
Research Funding - Curis; Merck; Regeneron (Inst)
 
Eric Schaefer
Employment - Highlands Oncology
Leadership - Exigent Research
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; G1 Therapeutics
 
Edward Arrowsmith
Employment - Tennessee Oncology
Stock and Other Ownership Interests - OneOncology
Consulting or Advisory Role - Flatiron Health
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calistoga Pharmaceuticals (Inst); Celgene (Inst); Cephalon (Inst); Chorus (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Dana-Farber Cancer Institute (Inst); Eisai (Inst); EMD Serono (Inst); Evelo Biosciences (Inst); Exelixis (Inst); F. Hoffmann LaRoche (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen Research & Development (Inst); Leap Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Millennium (Inst); Modra Pharmaceuticals (Inst); Novartis (Inst); Oncogenex (Inst); Onyx (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Sarah Cannon Research Institute (Inst); Takeda (Inst); Tolmar (Inst)
Travel, Accommodations, Expenses - Flatiron Health; OneOncology
Other Relationship - Sarah Cannon Research Institute (Inst)
 
Ki Chung
Consulting or Advisory Role - Castle Biosciences; Jazz Pharmaceuticals; Spring works
Research Funding - epizyme (Inst); MedImmune (Inst)
 
Eric Whitman
Consulting or Advisory Role - Bristol-Myers Squibb; Castle Biosciences; Merck Sharp & Dohme; Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Castle Biosciences; Merck Sharp & Dohme; Regeneron
Research Funding - Agenus (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BioNTech SE (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Genentech/Roche (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Merck Sharp & Dohme (Inst); OncoC4 (Inst); Oncolys BioPharma (Inst); OncoSec (Inst); Replimune (Inst); Seagen (Inst); Takeda (Inst); Toray Industries (Inst)
Patents, Royalties, Other Intellectual Property - Lighted Polyhedral surgical retractor; Nerve monitoring dissection device
 
Ulka Vaishampayan
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Exelixis; Gilead Sciences; Janssen Oncology; Merck Serono; Mural; Pfizer; Pfizer/Astellas; Sumitomo Pharma Oncology
Research Funding - Bristol-Myers Squibb; Merck KGaA
 
Svetlana Shpyro
Employment - BioNTech
 
Qiong Wang
Employment - BioNTech SE
Stock and Other Ownership Interests - BioNTech SE
Travel, Accommodations, Expenses - BioNTech SE
 
Juanjuan Su
Employment - OncoC4
 
Chris Leung
Employment - OncoC4
 
Kazuharu Kai
Employment - Allogene Therapeutics; OncoC4
Stock and Other Ownership Interests - Allogene Therapeutics; Karyopharm Therapeutics; Nektar
 
Yang Liu
Employment - OncoC4
Leadership - OncoC4
Stock and Other Ownership Interests - OncoC4
Patents, Royalties, Other Intellectual Property - OncoC4
Travel, Accommodations, Expenses - OncoC4
 
Pan Zheng
Employment - OncoC4
Leadership - OncoC4
Stock and Other Ownership Interests - OncoC4
Patents, Royalties, Other Intellectual Property - Patent on ONC-392, a new next generation anti-CTLA-4 antibody.
 
Tianhong Li
Honoraria - Bristol-Myers Squibb US
Consulting or Advisory Role - Bristol Myers Squibb; Janssen
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Chugai Pharma USA (Inst); Duality Biologics (Inst); Genentech (Inst); Jounce Therapeutics (Inst); LabyRx Immuno-Oncology (Inst); Lung Cancer Mutation Consortium (Inst); Merck (Inst); Novartis (Inst); OncoImmune/OncoC4 (Inst); RasCal (Inst); Tempus (Inst); Xilio Therapeutics (Inst)